{"id":13502,"date":"2010-12-13T09:30:00","date_gmt":"2010-12-13T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/boom-di-accordi-fra-aziende\/"},"modified":"2010-12-13T09:30:00","modified_gmt":"2010-12-13T08:30:00","slug":"boom-di-accordi-fra-aziende","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/boom-di-accordi-fra-aziende\/","title":{"rendered":"Boom of agreements between companies"},"content":{"rendered":"

<\/font><\/font><\/span><\/p>\n

<\/font><\/font><\/span><\/p>\n

Boom of agreements signed between pharmaceutical companies in 2010, with the aim of expanding into new business areas, above all oncology: the increase compared to the previous year was 20%, according to MedTrack data, the biomedical database of Life Science Analytics.<\/p>\n

<\/font><\/font><\/span><\/p>\n

Pfizer topped the list, with 51 agreements signed up to October 2010, followed by Sanofiaventis (50), Novartis (49), Roche (46) and GlaxoSmithKline (44). In sixth position is Bayer with 31 agreements, followed by Teva (30), AstraZeneca (25) and Abbott Laboratories (20). In tenth place, with 18 agreements, tied are Eli Lilly, Johnson & Johnson and Merck & Co. <\/p>\n

<\/font><\/font><\/span><\/p>\n

Sarah Terry, president of Life Science Analytics, highlights that "the most noteworthy case is that of the French Sanofi, which has climbed to second place from 14th last year and has closed only one less deal than the first in the ranking". As for the therapeutic areas, the 24% of the agreements concerns oncology, followed by diseases of the nervous system (14%) and infectious (8%).<\/p>\n

<\/font><\/font><\/span><\/p>\n

Barbara Di Chiara \u2013 Pharmakronos \u2013 December 13, 2010<\/span><\/em><\/strong><\/p>","protected":false},"excerpt":{"rendered":"

Boom di accordi firmati fra aziende farmaceutiche nel 2010, con l’obiettivo di espandersi in nuove aree di business, soprattutto l’oncologia: l’aumento rispetto all’anno precedente è stato del 20%, secondo i dati MedTrack, la banca dati biomedici di Life Science Analytics. Pfizer è in cima alla lista, con il 51 intese firmate fino a ottobre 2010, …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13502","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13502"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13502\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}